Return to Vaccination News Home Page
Subscribe to the Vaccination NewsLetter
View past & current Scandals (columns by Sandy Mintz)
Search This Site using keywords

| Ann Intern Med. 2003 May 6;138(9):697-704. |
Duration of antibiotic therapy for early Lyme disease. A
randomized, double-blind, placebo-controlled trial.
Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P,
Dornbush R, Singh B, Nadelman RB.
Division of Infectious Diseases, New York Medical College, Room 245, Munger
Pavilion, Valhalla, New York 10595, USA.
BACKGROUND: Treatment of patients with early Lyme disease has trended toward
longer duration despite the absence of supporting clinical trials. OBJECTIVE: To
evaluate different durations of oral doxycycline treatment and the combination
of oral doxycycline and a single intravenous dose of ceftriaxone for treatment
of patients with early Lyme disease. DESIGN: Randomized, double-blind,
placebo-controlled trial. SETTING: Single-center university hospital. PATIENTS:
180 patients with erythema migrans. INTERVENTION: Ten days of oral doxycycline,
with or without a single intravenous dose of ceftriaxone, or 20 days of oral
doxycycline. MEASUREMENTS: Outcome was based on clinical observations and
neurocognitive testing. Efficacy was assessed at 20 days, 3 months, 12 months,
and 30 months. RESULTS: At all time points, the complete response rate was
similar for the three treatment groups in both on-study and intention-to-treat
analyses. In the on-study analysis, the complete response rate at 30 months was
83.9% in the 20-day doxycycline group, 90.3% in the 10-day doxycycline group,
and 86.5% in the doxycycline-ceftriaxone group (P > 0.2). The only patient with
treatment failure (10-day doxycycline group) developed meningitis on day 18.
There were no significant differences in the results of neurocognitive testing
among the three treatment groups and a separate control group without Lyme
disease. Diarrhea occurred significantly more often in the
doxycycline-ceftriaxone group (35%) than in either of the other two groups (P <
0.001). CONCLUSIONS: Extending treatment with doxycycline from 10 to 20 days or
adding one dose of ceftriaxone to the beginning of a 10-day course of
doxycycline did not enhance therapeutic efficacy in patients with erythema
migrans. Regardless of regimen, objective evidence of treatment failure was
extremely rare.
PMID: 12729423 [PubMed - indexed for MEDLINE]
Return to Vaccination News Home Page
DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.